N
ε -(carboxymethyl) lysine (CML); LDL receptor; SREBP cleavageactivating protein; diabetic nephropathy TYPE 2 DIABETES, WHICH AFFECTS 8 -10% of the population worldwide, is a group of metabolic disorders characterized by insulin resistance, chronic hyperglycemia, hypertension, dyslipidaemia, proteinuria, and inflammation. It has been shown that 30% of patients with type 2 diabetes may develop microalbuminuria and diabetic nephropathy. Although multiple risk factors are involved, hyperglycemia seems to have an important role in the pathogenesis of complications which affect several organs, such as blood vessels and the kidney (1). Hyperglycemia is accompanied by an accelerated rate of advanced glycation end products (AGEs) formation, which is formed by the nonenzymatic reaction between reducing sugars and free amino groups of proteins (33) . N ε -(carboxymethyl) lysine (CML) is one of the major AGEs in vivo (24) , and its levels increase in tissues of diabetic patients (6, 21) . The increased circulating CML and accumulation of CML in tissues have been recognized as a critical step in the pathogenesis of insulin resistance, dyslipidaemia, and diabetic nephropathy by unknown mechanisms (19, 36) .
Diabetic nephropathy, characterized by glomerulosclerosis, proteinuria, and decline in glomerular filtration rate is the major complication of type 2 diabetes and also the major cause of end-stage kidney disease in Western countries. However, the mechanisms by which hyperglycemia causes glomerulosclerosis remain unclear. Type 2 diabetes often exhibits an atherogenic lipid profile (high triglycerides and low HDL cholesterol) (35) . Recent clinical evidence suggests that some type 2 diabetes patients with higher cholesterol have a greater risk of developing secondary complications (22, 23) . Giansanti et al. (7) also observed significantly higher levels of hypercholesterolemia in type 2 diabetic patients with complications compared with the patients without complications, suggesting that cholesterol may play a very important role in development of the complications of type 2 diabetes. In recent years, a number of studies have shown that the histological features of glomerulosclerosis are similar to the changes observed in atherosclerosis, and the term "glomerular atherosclerosis" has been proposed (4, 34) . Thus diabetic glomerulosclerosis and foam cell formation might therefore result from an increase in intracellular cholesterol accumulation by unknown mechanisms (10, 15, 17, 34) .
Multiple enzymes, carrier proteins, and lipoprotein receptors are involved in cholesterol homeostasis. The key molecule in maintaining intracellular cholesterol levels is sterol-regulatory element binding protein (SREBP) cleavage-activating protein (SCAP). SCAP regulates cholesterol homeostasis through its interactions with SREBP-1 and -2. SREBP-2 is more selective than SREBP-1 in controlling gene expression of 3-hydroxy-3-methylclutaryl (HMG)-CoA reductase (HMG-CoAR) and the LDL receptor (LDLr). SCAP has been identified as a cholesterol sensor and chaperone of SREBP-2. When the cellular demand for cholesterol rises, SCAP shuttles SREBPs from the endoplasmic reticulum (ER) to the Golgi, where they are cleaved by two proteases (site 1 and site 2 proteases). The cleaved N-terminal fragment (nSREBP) enters the nucleus, binds to the sterol-regulatory elements in the HMG-CoAR and LDLr promoters, and increases these gene transcriptions (3, 9) . Meanwhile, SCAP is glycosylated by the sequential action of Golgi enzymes ␣-mannosidase I, ␣-mannosidase II, and GlcNAc transferase I (5, 32) before returning to the ER. The modification of SCAP plays an important role in the cycling of SCAP between the ER and Golgi (25) . However, a high intracellular concentration of cholesterol prevents transport of the SCAP-SREBP complex from the ER to the Golgi and downregulates HMG-CoAR and LDLr expression. This feedback regulation mediated by SCAP prevents intracellular cholesterol overloading under physiological conditions.
Since CML can alter enzymatic activity, decrease ligand binding, modify protein half-life, and alter immunogenicity (33) , the present studies were designed to investigate whether CML could disrupt the SCAP-mediated feedback regulation for HMG-CoAR and LDLr by increasing SCAP gene transcription and protein glycosylation by Golgi enzymes, thereby enhancing the cycling of SCAP between the ER and the Golgi. This increases lipid accumulation by activating HMG-CoAR and LDLr in human mesangial cells.
MATERIALS AND METHODS
Cell culture. An established stable human mesangial cell line (HMCs; kindly donated by Dr. J. D. Sraer, Hopital Tenon, Paris, France) were cultured in RPMI-1640 medium with 10% fetal calf serum, 2 mmol/l glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. All experiments were carried out in serum-free RPMI-1640 medium containing 0.2% BSA, 2 mmol/l glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. All reagents for cell culture were obtained from Sigma (Poole, Dorset, UK). CML, which is produced by organic synthesis (no material of animal or human origin is used), was obtained from NeoMPS (Strasbourg, France).
LDL preparation. The plasma containing antioxidants (100 mol/l BHT and 20 mol/l EDTA) was adjusted to a density of 1.019 g/ml by adding sodium bromide (NaBr), and centrifuged at 60,000 rpm for 22 h at 4°C using a 70 Ti Rotor to remove VLDL and IDL. Next, the density was adjusted to 1.063 g/ml and centrifuged at 60,000 rpm for 22 h at 4°C. The LDL fraction on the top layer was aspirated and desalted by a PD-10 column. The LDL protein concentration was measured by a Lowry assay (28) .
Morphological examination. HMCs were plated in chamber slides (Becton Dickinson, Oxford, UK) and incubated in serum-free experimental medium in the absence or presence of 50 g/ml CML alone, CML plus 200 g/ml LDL, and LDL alone. After 24-h incubation, the cells were washed three times in PBS, fixed for 30 min with 5% formalin solution in PBS, stained with Oil Red O for 30 min, and counterstained with hematoxylin for another 5 min. Finally, the cells were examined by light microscopy.
Measurement of intracellular cholesterol. HMCs in six-well plates were cultured for 24 h in serum-free experimental medium in the absence or presence of 50 g/ml CML alone, CML plus 200 g/ml LDL, and LDL alone. Cells were then washed twice in PBS, intracellular lipids were extracted in a chloroform/methanol (2:1) mix and dried under a vacuum, and the total cholesterol (TC), free cholesterol (FC), and cholesterol ester content were measured by an enzymatic assay normalized by total cell proteins determined by the Lowry assay as described previously (cholesterol ester ϭ total cholesterol Ϫ free cholesterol) (20) .
Total RNA isolation and real-time quantitative PCR. Total RNA was isolated from cultured HMCs using TRIzol (Ambion, Huntingdon, UK). Total RNA (1 g) was used as a template for RT with a High Capacity cDNA RT Kit from ABI (Applied Biosystems, Warrington, UK). Real-time RT-PCR was performed in an ABI 7000 Sequence Detection System using SYBR Green dye according to the manufacturer's protocol (Applied Biosystems). All the PCR primers were designed by Primer Express Software V2.0. (Table 1) .
Protein isolation and Western blot analysis. Identical amounts of protein from whole-cell extract or nuclear extract were denatured and then subjected to electrophoresis on an 8% SDS polyacrylamide gels in a Bio-Rad miniprotein apparatus (Bio-Rad Laboratories, Hemel Hempstead, UK). Electrophoretic transfer to nitrocellulose was accomplished at 100 V, 350 mA for 1-2 h. The membrane was then blocked with 5% skim milk for 1 h at room temperature and probed with the following antibodies: chicken anti-human LDLr polyclonal antibody (Abcam, Cambridge, UK), goat anti-human nSREBP-2 polyclonal antibody (Santa Cruz Biotechnology, Wiltshire, UK), goat anti-human SCAP polyclonal antibody (Santa Cruz Biotechnology), rabbit anti-human HMG-CoAR polyclonal antibody (Millipore, Watford, UK), and rabbit anti-human ␤-actin polyclonal antibody (Sigma) in antibody dilution buffer (1% BSA in PBST). A goat anti-chicken or rabbit anti-goat or goat anti-rabbit horseradish peroxidase-labeled antibody (Abcam) was diluted in antibody dilution buffer. Finally, detection procedures were performed using an ECL Advance Western blotting detection kit and autoradiography was performed on Hyperfilm ECL (Amersham Bioscience, Buckinghamshire, UK).
Protein degradation. For a protein stability assay, HMCs were treated with cycloheximide (CHX; 50 mol/l) in the presence or absence of CML for different times. Total proteins prepared for SCAP degradation were resuspended in Complete Lysis Buffer (10 mmol/l DTT, lysis buffer, protease inhibitor cocktail). DTT (1:1,000) and a protease inhibitor cocktail (1:100) were added fresh to the buffer just before use. An equal amount of protein was subjected to Western blotting.
Plasmid constructions. A green fluorescent protein (GFP)-SCAP expression construct was made by ligating human SCAP cDNA into the Bst͟E-XbaI sites of the pEGFP-C1 vector.
Confocal microscopy. HMCs were plated on chamber slides and incubated in growth medium for 24 h. The cells were subsequently transfected with pEGFP-SCAP using Effectene Transfection Reagent (Qiagen, West Sussex, UK) according to the manufacturer's protocol. The transfected cells were incubated with or without 200 g/ml of LDL in the absence or presence of CML (50 g/ml). After 24 h, the cells were washed with PBS, fixed in 5% formalin solution for 30 min, permeablized with 0.25% of Triton X-100 for 15 min, and stained with mouse anti-Golgin-97 antibody (Invitrogen, Paisley, UK) for 1 h at room temperature. After washing, the cells were further stained by a secondary fluorescent antibody (goat anti-mouse Alexa Fluor 594) for 1 h. Cells were then imaged by confocal microscopy using a Zeiss LSM 510 Meta (Carl Zeiss, Hertfordshire, UK). The Golgi area was LDLr 5=-CTGTGGGCTCCATAGGCTATCT-3= sense 5=-GCGGTCCAGGGTCATCTTC-3= antisense SCAP 5=-ACTGGACTGAAGGCAGGTCAA-3= sense 5=-GCCTCTAGTCTAGGTCCAAAGAGTTG-3= antisense SREBP-2 5=-CGATGCCCTTCAGGAGCTT-3= sense 5=-GCGCCAGGAGAACATGGT-3= antisense HMG-CoAR 5=-TCTGGCAGTCAGTGGGAACTATT-3= sense 5=-CCTCGTCCTTCGATCCAATTT-3= antisense ␣-Mannosidase I 5=-TGGTATTG GAAGGAACTGGCC-3= sense 5=-GCCAGAATACTGCTGCCTCC-3= antisense ␣-Mannosidase II 5=-AATGGGACACTGAACCCCTTC-3= sense 5=-CGTTATGGGAATGAGGCACC-3= antisense ␤-Actin 5=-CCTGGCACCCAGCACAAT-3= sense 5=-GCCGATCCACACGGAGTACT-3= antisense LDLr, LDL receptor; SCAP, sterol-regulatory element binding protein (SREBP) cleavage-activating protein; HMG-CoAR, 3-hydroxy-3-methylclutaryl-CoA reductase.
selected, and the colocalizing pixels in the selected area were measured. The colocalization coefficient was calculated using Carl Zeiss LSM5 software.
Preparation of microsomes. Treated HMCs on two 150-cm 2 culture flasks were rinsed twice with PBS by incubating with 2 ml of PBS, 2 mmol/l of EDTA for 5-10 min. The cells were pelleted by centrifugation at 500 g for 5 min. The pellet was washed with PBS, recentrifuged, resuspended into 2 ml of low-ionic strength buffer (10 mmol/l Tris·HCl, pH 7.5, 0.5 mmol/l MgCl 2, 1 mmol/l phenylmethanesulfonyl fluoride, 100 U/ml aprotinin), and then incubated on ice for 15 min. The isotonic homogenate was made by addition of 2 ml of 0.5 mol/l sucrose, 0.3 mol/l KCl, 6 mmol/l ␤-mercaptoethanol, 40 mol/l CaCl2, 10 mmol/l Tris·HCl, pH 7.5, and then centrifuged at 8,000 g for 20 min at 4°C. The supernatant was transferred to a polycarbonate tube containing 0.9 ml of 2.5 mol/l KCl, then centrifuged at 120,000 g for 1 h at 4°C. The pellet was washed twice and then resuspended in 200 l of buffer (0.25 mol/l sucrose, 0.15 mol/l KCl, 3 mmol/l ␤-mercaptoethanol, 20 mol/l CaCl2, 10 mmol/l Tris·HCl, pH 7.5).
Enzymatic assay of ␣-mannosidase. ␣-Mannosidase activity was determined using a previously described enzyme-based method (18) Data analysis. In all experiments, groups of data were evaluated for significance by one-way ANOVA. Data were considered significant if the P value was Ͻ0.05.
RESULTS

Oil
Red O staining and intracellular cholesterol assay. We checked lipid accumulation in HMCs in response to CML and LDL. CML increased Oil Red O staining in the absence or presence of LDL in HMCs (Fig. 1A) . Intracellular cholesterol levels were also quantified using an enzymatic assay. Intracel- lular cholesterol ester was increased in CML-treated cells in the absence or presence of a high concentration of LDL (Fig.  1B) . These data suggest that CML results in intracellular cholesterol accumulation and foam cell formation.
Effects of CML on HMG-CoAR, LDLr, and SREBP-2 expression.
We investigated effects of CML on the expression of HMG-CoAR, LDLr, and SREBP-2. CML upregulated both mRNA ( Fig. 2A) and protein (Fig. 2, B and C) expression of HMG-CoAR, LDLr, and SREBP-2 and overrode the suppression of these molecules induced by a high concentration of LDL. These results suggest that CML may increase HMGCoAR-mediated cholesterol synthesis and LDLr-mediated cholesterol uptake by activating the SREBP pathway.
Effect of Golgi enzyme inhibitors. Kifunensine and swainsonine are inhibitors of ␣-mannosidase I and ␣-mannosidase II, enzymes which are required for the glycosylation of SCAP. Fig. 3 . Effects of Golgi enzyme inhibitors kifunensine and swainsonine in HMCs. HMCs were exposed to 2.5 g/ml kifunensine plus 5 g/ml swainsonine in the presence of 50 g/ml CML alone or 50 g/ml CML plus 200 g/ml LDL for 24 h. Intracellular cholesterol levels [total (TC), free (FC), and ester content (EC)] were assayed as described in MATERIALS These inhibitors decreased cholesterol levels induced by CML in the absence or presence of a high concentration of LDL (Fig. 3A) and also reduced HMG-CoAR, LDLr, and SREBP-2 expression induced by CML at both the mRNA and the protein levels (Fig. 3, B-D) , suggesting that the Golgi enzyme inhibitors prevent cholesterol accumulation in HMCs induced by CML.
Effects of CML on SCAP expression and intracellular translocation. We investigated effects of CML on the expression of SCAP, which is a cholesterol sensor and chaperone of SREBP-2. CML upregulated levels of SCAP mRNA (Fig. 4A) and protein (Fig. 4, B and C) and overrode the suppression of SCAP induced by a high concentration of LDL.
Using immunofluorescent staining, we investigated the effect of CML on the translocation of SCAP-escorting SREBP-2 from the ER to the Golgi in HMCs transiently expressing pEGFP-SCAP. By staining pEGFP-SCAP-transfected HMCs with anti-human Golgin-97 antibody, we demonstrated that LDL reduced SCAP accumulation in the Golgi by inhibiting SCAP translocation from the ER to the Golgi. However, CML increased SCAP accumulation in the Golgi by enhancing translocation of SCAP from the ER to the Golgi even in the presence of a high concentration of LDL (Fig. 5A) . The colocalization efficiency of SCAP in the Golgi was increased in the CML-treated cells in the absence or presence of LDL (Fig. 5B) . These results suggest that CML may disrupt SCAPmediated feedback regulation for HMG-CoAR and LDLr by increasing SCAP expression and SCAP translocation from the ER to the Golgi.
Effect of CML on SCAP stability. To evaluate the protein stability of SCAP in the absence or presence of CML in HMCs, we used Western blotting to estimate the amount of protein remaining at various time points (0, 2, 4, 8, 24, or 48 h) after HMCs incubated with CHX, a protein synthesis inhibitor (Fig. 6, A and B) . We demonstrated that SCAP levels in HMCs in serum-free experimental medium declined in a time-dependent manner without CML. However, the decline of SCAP protein levels was prevented by CML at all time points, suggesting that CML may increase SCAP protein stability. Effect of CML on Golgi enzyme mRNA level and activity. Next, we investigated the effects of CML on the expression of the Golgi enzymes ␣-mannosidase I and ␣-mannosidase II, which are required for SCAP glycosylation. CML upregulated the mRNA expression of ␣-mannosidase I and ␣-mannosidase II in the absence or presence of LDL (Fig. 7A) . We also examined ␣-mannosidase activity. Consistent with enhanced enzyme mRNA expression, CML also increased enzyme protein activity (Fig. 7B) .
DISCUSSION
In the kidney, the formation of glomerular foam cells is encountered in diabetic glomerulosclerosis, for which mesangial lipid accumulation is an important factor (10, 11, 13, 17) . We detected intracellular cholesterol content with different concentrations of CML (12.5, 50, and 100 g/ml) in the absence or presence of LDL. The maximal effect was reached at 50 g/ml (data not shown) of CML, which was used for the all experiments in the study. Using the Oil Red O staining, the present studies show that CML caused massive lipid accumulation in HMCs, which was confirmed by an intracellular cholesterol ester quantitative assay in CML-treated cells. This result is consistent with the observation that there are excessive amounts of lipid deposits in the diabetic kidney, which is associated with increased mesangial expansion, matrix protein accumulation, and tubulointerstitial fibrosis, resulting in diabetic glomerulosclerosis (17, 34) .
The generally accepted mechanism of lipid accumulation in cells involves uptake of modified LDL (usually oxidized LDL) via the type A scavenger receptor family (ScrA) (2) . Although we have demonstrated that inflammatory cytokines cause lipid accumulation in HMCs by inducing ScrA (30) , it seems that the main lipoprotein receptor in both HMCs and tubular cells is LDLr. We have previously demonstrated that inflammatory cytokines increased LDL cholesterol uptake by disrupting LDLr feedback regulation (26, 27, 29 -31) and that lipid accumulation in HMCs induced by cytokines could not be inhibited by poly I, a scavenger receptor blocker (16) . Instead, this accumulation was blocked by heparin, which removes LDL bound to the cell surface (8) , suggesting that the LDLr pathway is involved in cholesterol accumulation in HMCs induced by inflammation. In this study, we demonstrated that CML accelerated lipid accumulation in HMCs by increasing both mRNA and protein expression of HMG-CoAR and LDLr, therefore increasing cholesterol synthesis and uptake and causing mesangial foam cell formation independently of scavenger receptors.
Next, we examined the effects of CML on expression and intracellular translocation of SCAP and SREBP-2, two important molecules regulating HMG-CoAR and LDLr expression. Our result showed that CML increased both mRNA and protein expression of SCAP. It seems that the ER retention factor for SCAP is quantitatively limited in the ER and may be present in insufficient concentrations to retain the increased SCAP levels in the presence of CML (27) . Therefore, increased SCAP expression results in SCAP translocation from the ER to the Golgi as shown in the immunofluorescent staining in this study. This abnormal escape of the SCAP-SREBP2 complex carries more SREBP-2 to the Golgi for cleavage which in- creased levels of nSREBP-2, increasing expression of HMGCoAR and LDLr even in the presence of a high concentration of LDL which would normally inhibit this process and prevent cholesterol overloading. These data suggest that CML disrupts cholesterol-mediated feedback regulation for HMG-CoAR and LDLr by increasing SCAP expression and translocation from the ER to the Golgi. SREBP-2 is a key regulatory factor for both LDLr and HMG-CoAR transcription. It seems that CML significantly increased SREBP2 expression, but less efficiently increased both LDLr and HMG-CoAR expression. This may be because CML also activates a factor inhibiting LDLr expression. For example, it has been reported that CML increases oxidation of LDL, producing more ox-LDL which may inhibit LDLr transcription (11a). This may explain why expression of SREBP, to a lesser degree than LDLr and HMG-CoAR, was increased by CML. When SCAP translocates from the ER to the Golgi, its carbohydrates are successively modified by ␣-mannosidase I, GlcNAc transferase I, and ␣-mannosidase II before it cycles back to the ER (14, 25) . Inhibitors of ␣-mannosidase I and ␣-mannosidase II inhibit this process (12) . Recent studies have indicated that interaction of CML with RAGE causes oxidative stress and activation of NF-B via multiple intracellular signal pathways, which can alter enzymic activity of mannosidases and modify the protein half-life. Our results demonstrated that CML increased mRNA expression and enzyme activity of Golgi ␣-mannosidases, which can result in glycosylation of SCAP as demonstrated previously (25) . We have also shown that CML increased SCAP stability as shown in Fig. 6 , probably by preventing SCAP degradation and prolonging SCAP half-life. It seems that SCAP Golgi glycosylation by CML enhances the stability and recycling of SCAP between the ER and Golgi, increasing intracellular cholesterol levels by activating HMG-CoAR and LDLr. Interestingly, kifunensine (an inhibitor of ␣-mannosidase I) and swainsonine (an inhibitor of ␣-mannosidase II) reduced CML-induced cholesterol levels by inhibiting SREBP-2 activation and expression of HMG-CoAR and LDLr.
In summary, this study demonstrates that CML increases expression and potential glycosylation of SCAP in the Golgi by increasing enzyme activity of Golgi ␣-mannosidases, thereby causing an abnormal translocation of SCAP from the ER to the Golgi and enhancing recycling of the SCAP-SREBP complex between the ER and the Golgi. These processes increase SREBP cleavage and produce more nSREBP-2, which consequently activates HMG-CoAR and LDLr expression and lipid accumulation in HMCs. These results may improve our understanding of the molecular mechanisms of diabetic glomerulosclerosis and also suggest that SCAP transcription and intracellular translocation could be a useful biomarker for prediction of progression of diabetic nephropathy and that anti-AGEs or Golgi enzyme inhibitors may be useful adjunctive therapeutic agents in the management of diabetic glomerulosclerosis. 
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